{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T02:39:47Z","timestamp":1778726387209,"version":"3.51.4"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["www.neurology.org"],"crossmark-restriction":true},"short-container-title":["Neurology"],"published-print":{"date-parts":[[2025,2,25]]},"DOI":"10.1212\/wnl.0000000000210142","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T21:00:16Z","timestamp":1738270816000},"update-policy":"https:\/\/doi.org\/10.1212\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS"],"prefix":"10.1212","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3155-2775","authenticated-orcid":false,"given":"Jo\u00e3o J.","family":"Cerqueira","sequence":"first","affiliation":[{"name":"Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga, Portugal;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9650-6222","authenticated-orcid":false,"given":"Achim","family":"Berthele","sequence":"additional","affiliation":[{"name":"Department of Neurology, School of Medicine, Technical University of Munich, Germany;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7689-2533","authenticated-orcid":false,"given":"Bruce A.C.","family":"Cree","sequence":"additional","affiliation":[{"name":"Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-0479","authenticated-orcid":false,"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[{"name":"Neurology Unit, Neurophysiology Service, Neurorehabilitation Unit, Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy;"},{"name":"Vita-Salute San Raffaele University, Milan, Italy;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2207-3708","authenticated-orcid":false,"given":"Gabriel","family":"Pardo","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Center of Excellence, Oklahoma Medical Research Foundation, Oklahoma City;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2712-0200","authenticated-orcid":false,"given":"Owen R.","family":"Pearson","sequence":"additional","affiliation":[{"name":"Department of Neurology, Morriston Hospital, Swansea, United Kingdom;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0351-9639","authenticated-orcid":false,"given":"Anthony","family":"Traboulsee","sequence":"additional","affiliation":[{"name":"Division of Neurology, University of British Columbia, Vancouver, Canada;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8799-8202","authenticated-orcid":false,"given":"Tjalf","family":"Ziemssen","sequence":"additional","affiliation":[{"name":"Center of Clinical Neuroscience, Department of Neurology, University Clinic Carl Gustav Carus, Dresden University of Technology, Germany;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1539-9830","authenticated-orcid":false,"given":"Timothy","family":"Vollmer","sequence":"additional","affiliation":[{"name":"Department of Neurology, Rocky Mountain Multiple Sclerosis Center at Anschutz Medical Campus, University of Colorado Denver;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1019-5468","authenticated-orcid":false,"given":"Corrado","family":"Bernasconi","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland;"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2881-6041","authenticated-orcid":false,"given":"Corey R.","family":"Mandel","sequence":"additional","affiliation":[{"name":"Genentech Inc., San Francisco, CA;"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0600-4552","authenticated-orcid":false,"given":"Inessa","family":"Kulyk","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3717-5168","authenticated-orcid":false,"given":"Cathy","family":"Chognot","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1466-1542","authenticated-orcid":false,"given":"Catarina","family":"Raposo","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5828-2336","authenticated-orcid":false,"given":"Hans-Martin","family":"Schneble","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland;"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6836-6099","authenticated-orcid":false,"given":"Gian-Andrea","family":"Thanei","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland;"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0719-0807","authenticated-orcid":false,"given":"Elodie","family":"Incera","sequence":"additional","affiliation":[{"name":"IQVIA Inc., Paris, France; and"}]},{"given":"Eva K.","family":"Havrdov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Neurology and Center of Clinical Neuroscience, First Medical Faculty, General University Hospital and Charles University, Prague, Czech Republic."}]}],"member":"276","reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181e24136"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211039648"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/20552173231187810"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13236"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8040071"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30151-6"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy151"},{"key":"e_1_3_8_9_2","volume-title":"Ocrevus (Ocrelizumab) [Full Prescribing Information]","author":"Genentech","year":"2020","unstructured":"Genentech. Ocrevus (Ocrelizumab) [Full Prescribing Information]. 2020. Accessed January 20, 2020. gene.com\/download\/pdf\/ocrevus_prescribing.pdf."},{"key":"e_1_3_8_10_2","volume-title":"Ocrevus [Summary of Product Characteristics]","author":"European Medicines Agency","year":"2021","unstructured":"European Medicines Agency. Ocrevus [Summary of Product Characteristics]. 2021. Accessed January 18, 2021. ema.europa.eu\/en\/documents\/product-information\/ocrevus-epar-product-information_en.pdf."},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.1.361"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606468"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010376"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22366"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00095-8"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.1006\/nimg.2002.1040"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2013.10.015"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51524"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103203"},{"key":"e_1_3_8_21_2","doi-asserted-by":"crossref","unstructured":"Hauser SL Kappos K Chognot C et al. Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Poster presented at ECTRIMS 2022. P326.","DOI":"10.1016\/j.msard.2023.105308"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102192"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102725"},{"key":"e_1_3_8_24_2","unstructured":"Vivli Inc. A Global Clinical Research Data Sharing Platform. 2024. Accessed September 17 2024. vivli.org\/."},{"key":"e_1_3_8_25_2","unstructured":"Vivli Inc. Our Members: Roche. 2024. Accessed September 17 2024. https:\/\/vivli.org\/ourmember\/roche\/."},{"key":"e_1_3_8_26_2","unstructured":"F. Hoffmann-La Roche Ltd. Our Commitment to Transparency of Clinical Study Information. 2024. Accessed September 17 2024. https:\/\/www.roche.com\/research_and_development\/who_we_are_how_we_work\/clinical_trials\/our_commitment_to_data_sharing.htm."},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012700"},{"key":"e_1_3_8_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq118"},{"key":"e_1_3_8_29_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007032"},{"key":"e_1_3_8_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy154"},{"key":"e_1_3_8_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104662"},{"key":"e_1_3_8_32_2","unstructured":"Derfuss T Bermel R Lin CJ et al. Risk factors for serious infections in patients with MS receiving long-term ocrelizumab treatment: multivariate analyses. Poster presented at EAN 2022. EPO-403."},{"key":"e_1_3_8_33_2","doi-asserted-by":"crossref","unstructured":"Hauser SL Kappos L Montalban X et al. Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and progressive multiple sclerosis. Poster presented at ECTRIMS 2023. P304.","DOI":"10.1016\/j.msard.2023.105308"},{"key":"e_1_3_8_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21437"},{"key":"e_1_3_8_35_2","unstructured":"Hartung H Brochet B Freedman M et al. Treatment-naive patients with early-stage relapsing-remitting multiple sclerosis showed low disease activity after 2-year ocrelizumab therapy with no new safety signals: the Phase IIIb ENSEMBLE study. Paper presented at: Multiple Sclerosis Journal 2022."},{"key":"e_1_3_8_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30067-3"}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/WNL.0000000000210142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T21:00:28Z","timestamp":1738270828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.0000000000210142"}},"subtitle":["Nine-Year Data From the OPERA Studies Open-Label Extension"],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,2,25]]}},"alternative-id":["10.1212\/WNL.0000000000210142"],"URL":"https:\/\/doi.org\/10.1212\/wnl.0000000000210142","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"2024-02-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e210142"}}